Christensen King & Associates Investment Services’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45K Hold
28,327
0.02% 108
2026
Q1
$5.83K Hold
28,327
﹤0.01% 105
2025
Q4
$44.8K Buy
28,327
+1,119
+4% +$1.79K 0.02% 106
2025
Q3
$28.8K Buy
27,208
+2,878
+12% +$4.98K 0.01% 106
2025
Q2
$38.9K Buy
24,330
+12,420
+104% +$19.8K 0.02% 101
2025
Q1
$16.7K Buy
11,910
+1,334
+13% +$2.34K 0.01% 97
2024
Q4
$15.5K Buy
10,576
+300
+3% +$1.23K 0.01% 92
2024
Q3
$54.9K Buy
+10,276
New +$75.2K 0.03% 99
2024
Q1
Sell
-8,180
Closed -$64.5K 99
2023
Q4
$64.5K Buy
+8,180
New +$69.2K 0.03% 93

Other funds holding OTLK

Christensen King & Associates Investment Services's OTLK Position: Q2 2026 in Review

Christensen King & Associates Investment Services held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 28,327 shares worth $45K. The position accounts for 0.02% of the portfolio, ranked #108.

Christensen King & Associates Investment Services first reported a position in OTLK in Q4 2023 and has held it in 9 quarters since. The position peaked at $64.5K in Q4 2023. 23 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Christensen King & Associates Investment Services held 28,327 shares of Outlook Therapeutics worth $45K as of Q2 2026.
  • Christensen King & Associates Investment Services left its Outlook Therapeutics share count unchanged in Q2 2026.
  • Outlook Therapeutics made up 0.02% of Christensen King & Associates Investment Services's portfolio in Q2 2026, its #108 holding.
  • Christensen King & Associates Investment Services first reported a position in Outlook Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Christensen King & Associates Investment Services's Outlook Therapeutics position peaked at $64.5K in Q4 2023.
  • 23 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Christensen King & Associates Investment Services's 13F filing for Q2 2026, filed 14 Jul 2026.